Celltrion Healthcare (Formerly Known As Celltrion)
1000 Marina Boulevard
About Celltrion Healthcare (Formerly Known As Celltrion)Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.
CEO: Jung Jini
Please click here for clinical trial information.
Tweets by Celltrion
78 articles with Celltrion Healthcare (Formerly Known As Celltrion)
Hikma Reaches Licensing Agreement With Celltrion for Third Biosimilar Product in the Middle East and North Africa
Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima, Remsima and Herzuma - in all its MENA markets.
Pfizer Release: One Year Maintenance and Switching Data in Patients with Crohn's Disease Support the Use of INFLECTRA (infliximab CT-P13) in IBD1
Pfizer and Celltrion Healthcare jointly announced the secondary outcomes from the phase III trial of INFLECTRA in CD at the 25th United European Gastroenterology Week.
Celltrion Healthcare Taps Oracle Health Sciences Safety Solutions To Help Bring Cost-Effective Life-Saving And Biosimilar Drugs To Market
Celltrion Healthcare: Biosimilar Trastuzumab Candidate, Ct-P6, Shown To Be Similar In Efficacy And Safety To Reference Trastuzumab In Breast Cancer Patients As Neoadjuvant And Adjuvant Treatment
Celltrion Healthcare Showcases Data Supporting The Efficacy And Safety Of Truxima (CT-P10, Biosimilar Rituximab) In Advanced Follicular Lymphoma And Rheumatoid Arthritis
Celltrion Healthcare Biosimilar Trastuzumab Candidate, CT-P6, Shown To Be Similar In Efficacy And Safety To The Reference Trastuzumab
Celltrion Healthcare Release: Truxima, The First Biosimilar Mab In Oncology, Granted EU Marketing Authorization
Celltrion Healthcare Release: New Statement From European Crohn's And Colitis Organisation Supports Switching To Biosimilar From Reference Product In Inflammatory Bowel Disease
Celltrion Healthcare Presents Positive Results For CT-P10, Biosimilar Rituximab Candidate, In Newly Diagnosed Advanced Stage Follicular Lymphoma
Celltrion Healthcare Showcases Data Supporting Efficacy And Safety Of Both CT-P10 And CT-P13 Biosimilars
Celltrion Announces Its Commitment To Develop Anti-Drug Antibody And Drug Concentration Assay To Enable Evidence-Based Decision-Making In anti-TNF Treatment
FDAAdvisoryCommittee.com Approves Celltrion’s INFLECTRA, the First Cheaper Version of Johnson & Johnson Blockbuster Remicade
FDA’s Arthritis Advisory Committee Recommends Approval Of Celltrion’s CT-P13, A Proposed Biosimilar Infliximab, For All Indications